CSIMarket Company Name, Ticker, Customers, else..
 
Eyepoint Inc   (NASDAQ: EYPT)
 
Price: $4.5800 $0.01 0.219%
Day's High: $4.690000057220459 Week Perf: 1.78 %
Day's Low: $ 4.49 30 Day Perf: -64.3 %
Volume (M): 1,901,800 52 Wk High: $ 19.11
Volume (M$): $ 0 52 Wk Avg: $13.47
Open: $4.53 52 Wk Low: $3.95



 Market Capitalization (Millions $) 39
 Shares Outstanding (Millions) 9
 Employees 214
 Revenues (TTM) (Millions $) 8
 Net Income (TTM) (Millions $) -272
 Cash Flow (TTM) (Millions $) -7
 Capital Exp. (TTM) (Millions $) 4

Business Description


Eyepoint Pharmaceuticals Inc is a specialty biopharmaceutical company that focuses on developing innovative and sustained-release therapeutics for treating various eye diseases. The company's primary goal is to improve patient outcomes and provide more convenient treatment options for ophthalmic conditions. Eyepoint employs advanced technology to develop unique drug delivery systems that can achieve long-lasting therapeutic effects with a single dose. Their product portfolio includes treatments for conditions such as macular edema, posterior uveitis, and other retinal diseases. Eyepoint Pharmaceuticals aims to transform the treatment landscape for eye diseases and enhance the quality of life for patients.


   Company Address: 480 Pleasant Street Watertown 2472 MA
   Company Phone Number: 926-5000   Stock Exchange / Ticker: NASDAQ EYPT


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
GKOS   -1.33%    
HROW        3.41% 
OCGN        3.03% 
OCUL        2.7% 
REGN        4.22% 
TARS        26.51% 
• View Complete Report
   



Clinical Study

EyePoint Pharmaceuticals Advances DURAVYU Trials A Promising Leap Towards New Treatments for Vision Loss,

Published Wed, Nov 19 2025 12:26 PM UTC

In a significant boost for the field of ophthalmology, EyePoint Pharmaceuticals has announced a positive recommendation from the Independent Data Safety Monitoring Committee (DSMC) regarding its pivotal Phase 3 trials for DURAVYU, specifically targeting the treatment of wet age-related macular degeneration (wet AMD). The favorable review was provided for two ongoing clinical...
Shares

EyePoint Pharmaceuticals Strengthens Employee Incentives with Stock Options Amid Financial Growth and Public Offering Success,

Published Mon, Mar 17 2025 11:00 AM UTC

EyePoint Pharmaceuticals Expands Employee Incentives and Strengthens Financial Position Amid Market ActivityWATERTOWN, Mass. March 17, 2025 EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company devoted to the development and commercialization of innovative therapeutics designed to enhance the quality of life for patients affected by serious retinal diseases, has recent...
Stock Market Announcement

Talent in Focus: EyePoint Pharmaceuticals Inducement Grants Spur Growth Potential Despite Dilution Risks,

Published Mon, Feb 17 2025 12:00 PM UTC

EyePoint Pharmaceuticals Boosts Talent with Inducement Grants: What It Means for InvestorsIn a significant move that reflects its continued commitment to fostering growth and attracting talent, EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) recently announced the granting of non-statutory stock options to new employees as part of their efforts to enhance their workforce. Thi...
Management Announcement

EyePoint Provides Company Update and Anticipated Development Milestones for 2025

Published Mon, Jan 13 2025 12:01 PM UTC

EyePoint Pharmaceuticals: Strategic Growth and Promising Developments in OphthalmologyIn an era where the pharmaceutical industry faces rigorous competition and rapid advancements, EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) is making noteworthy progress in its quest to provide innovative solutions for serious retinal diseases. The company’s latest updates reveal a stra...
Management Announcement

EyePoint Pharmaceuticals Initiates $100 Million Public Offering, Upsizes to $140 Million to Fuel Growth in Retinal Disease Treatments,

Published Mon, Oct 28 2024 9:14 PM UTC

EyePoint Pharmaceuticals Expands Growth Horizon with Major Public Offering: Insights and ImplicationsOn October 28, 2024, EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pioneering company focused on innovative therapeutics for retinal diseases, announced its intention to initiate an underwritten public offering of common stock worth $100 million. This strategic move under...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 5.17
Price to Sales (Expected) -
Price to Book 0.17
PEG (TTM) -

Financial Strength Current
Quick Ratio 7.47
Working Capital Ratio 8.19
Leverage Ratio (MRQ) 0.25
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -36.11 $
Revenues (TTM) 0.89 $
Cash Flow (TTM) -
Cash 32.54 $
Book Value 26.8 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 35,579
Net Income per Employee (TTM) -1,269,154
Receivable Turnover Ratio (TTM) 8.76
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.02

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -12532.47 %
Net Margin (MRQ) -12188.51 %
Net Cash Flow Margin (MRQ) -3463.94 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Eyepoint Inc's Segments

  Eyepoint Inc Outlook

On March 7 2024 the Eyepoint Inc provided following guidance

EyePoint Pharmaceuticals Inc. has released their financial results for the fourth quarter and full year of 2023, along with highlighting recent corporate developments. One of the most significant updates includes the announcement of positive topline efficacy and safety data from the Phase 2 DAVIO 2 trial of EYP-1901 in wet age-related macular degeneration (AMD). This study successfully met all primary and secondary endpoints, marking a significant milestone for the company.

Following these promising results, EyePoint Pharmaceuticals Inc. anticipates initiating the first Phase 3 clinical trial for EYP-1901 in the second half of 2024. This advancement in the development of EYP-1901 highlights the compan...





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.